Fungal Trans-kingdom Dynamics Linked to Responsiveness to Fecal Microbiota Transplantation (FMT) Therapy in Ulcerative Colitis
Irina Leonardi, Sudarshan Paramsothy, Itai Doron, Alexa Semon, Nadeem O Kaakoush, Jose C Clemente, Jeremiah J Faith, Thomas J Borody, Hazel M Mitchell, Jean-Frederic Colombel, Michael A Kamm, Iliyan D Iliev
Cell Host & Microbe | CELL PRESS | Published : 2020
Fecal microbiota transplantation (FMT) targeting gut microbiota has recently been successfully applied to ulcerative colitis. However, only a subset of patients responds to FMT, and there is a pressing need for biomarkers of responsiveness. Fungi (the mycobiota) represent a highly immunologically reactive component of the gut microbiota. We analyzed samples from a large randomized controlled trial of FMT for ulcerative colitis (UC). High Candida abundance pre-FMT was associated with a clinical response, whereas decreased Candida abundance post-FMT was indicative of ameliorated disease severity. High pre-FMT Candida was associated with increased bacterial diversity post-FMT, and the presence ..View full abstract
Awarded by US National Institutes of Health
Research in the Iliev laboratory is supported by the US National Institutes of Health (DK113136, DK121977 and AI137157), the Crohn's and Colitis Foundation Senior Research Award, the Helmsley Charitable Trust, the Irma T. Hirschl Career Scientist Award, pilot funding from the Center for Advanced Digestive Care (CADC), and the JRI for research in IBD. J.F.C. is supported by the Cutting-Edge Therapies for Ulcerative Colitis grant; H.M.M. is supported by a Lit-win IBD Pioneer Award from Crohn's and Colitis Foundation; I.L. is supported by fellowships from the Crohn's and Colitis Foundation.